THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00 2022-06-29 pm EDT
535.92 USD   +0.03%
06/14S&P Upgrades Thermo Fisher Scientific One Notch To 'A-' On Expected Leverage Below 3x and Strong Demand; Outlook Stable
MT
06/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
06/10Illumina Shares Drop 10% After CFO Departure
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific and Qatar Genome Program Announce Partnership to Advance Precision Medicine

05/23/2022 | 08:07am EDT

Thermo Fisher Scientific and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. The array, with about 800,000 variants, aims to help drive scientific research and insights into conditions including diabetes, cardiovascular and metabolic diseases, autism, inherited genetic disorders and cancer. Once available through Thermo Fisher’s global commercial channels in late 2022, the array is intended to provide a cost-effective alternative to whole genome sequencing for Arab populations, enabling increased diversity in large genome-wide studies. As part of the new agreement, the organizations will continue to refine algorithms and define clinically actionable content to assess polygenic risk scores, a measure of disease risk, and clinically relevant variants, including those related to pharmacogenomics.


© S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
06/14S&P Upgrades Thermo Fisher Scientific One Notch To 'A-' On Expected Leverage Below 3x a..
MT
06/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
06/10Illumina Shares Drop 10% After CFO Departure
DJ
06/09Illumina Says CFO Sam Samad to Depart July 8
DJ
06/09Thermo Fisher Scientific Inc Announces FDA Clears Thermo Scientific EliA RNA Pol III an..
CI
06/09Thermo Fisher Scientific Tests Get FDA Clearance
DJ
06/07Thermo Fisher Scientific Inc. Updates Applied Biosystems QuantStudio 5 Dx Real-Time PCR..
CI
06/06Thermo Fisher Scientific Inc. Showcases Solutions for Accelerating Next Generation Vacc..
CI
06/06Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine a..
BU
06/06Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 489 M - -
Net income 2022 6 837 M - -
Net Debt 2022 25 165 M - -
P/E ratio 2022 31,1x
Yield 2022 0,22%
Capitalization 210 B 210 B -
EV / Sales 2022 5,53x
EV / Sales 2023 5,25x
Nbr of Employees 130 000
Free-Float 88,7%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 535,92 $
Average target price 661,95 $
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors